FcZero-rAb? APC Anti-Human VE-cadherin/CD144 Rabbit Recombinant Antibody Proteintech APC-FcA98071

$299.00
In stock
SKU
APC-FcA98071

 

VE-cadherin, CDH5, CD144, Cadherin 5, 7B4 antigen

Formulation::PBS, Azide, BSA Formulation::PBS, Azide, BSA1
Applications:Flow Cytometry (FC) Formulation::PBS, Azide, BSA2
 Reactivity:Rabbit / IgG Formulation::PBS, Azide, BSA3
Type:Recombinant protein Predict reactive species Formulation::PBS, Azide, BSA4
RRID:1003 Formulation::PBS, Azide, BSA5
Storage Buffer:Protein A purification Formulation::PBS, Azide, BSA6
Background Information:Cadherins are a family of transmembrane glycoproteins that mediate calcium-dependent cell-cell adhesion and play an important role in the maintenance of normal tissue architecture. Vascular endothelial cadherin (VE-cadherin), also known as Cadherin-5 (CDH5) or CD144, is a member of the type II classical cadherin family of cell adhesion proteins (PMID: 21269602). VE-cadherin is expressed specifically in endothelial cells and mediates homophilic adhesion in the vascular endothelium (PMID: 1522121; 8555485; 21269602). VE-cadherin plays a role in the organization of lateral endothelial junctions and in the control of permeability properties of vascular endothelium (PMID: 1522121). VE-cadherin has also been shown to be required for angiogenesis (PMID: 16473763; 18162609). The calculated molecular weight of VE-cadherin is 88 kDa and the apparent molecular weight of 120-140 kDa is higher due to post-translational glycosylation and phosphorylation (PMID: 10460833; 29894844). Full-length VE-cadherin can be proteolytically cleaved to generate a fragment of 90-100 kDa (PMID: 9786462; 22064597). Formulation::PBS, Azide, BSA7
biogegep8 Formulation::PBS, Azide, BSA8
biogegep9 Formulation::PBS, Azide, BSA9
Formulation::PBS, Azide, BSA0 Applications:Flow Cytometry (FC)0

 

 

Reviews

Write Your Own Review
You're reviewing:FcZero-rAb? APC Anti-Human VE-cadherin/CD144 Rabbit Recombinant Antibody Proteintech APC-FcA98071
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.